This article has Open Peer Review reports available.
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
© Benusiglio et al; licensee BioMed Central Ltd. 2011
Received: 5 August 2010
Accepted: 19 March 2011
Published: 19 March 2011
Gastrointestinal relapse in patients with multiple myeloma is very rare and, when reported, always associated with a poor prognosis.
We describe the case of a 71-year-old Caucasian man who presented with life-threatening hematemesis and melena due to a digestive relapse of his multiple myeloma. Despite the active hemorrhage, we initiated a third-line treatment with lenalidomide. The response was spectacular and long-lasting.
Clinicians must consider digestive tract involvement in myeloma patients presenting with a gastrointestinal hemorrhage. Furthermore, myeloma patients do benefit from novel oral drugs, even when they are critically ill.
The involvement of the gastrointestinal tract years after an initial diagnosis of multiple myeloma (MM) is exceptional and, when reported, always associated with a poor prognosis [1–4]. We report the case of a 71-year-old man with MM who had been heavily pre-treated and who presented with hematemesis and melena due to a gastrointestinal relapse of his disease. The bleeding lasted for over two weeks and soon became life-threatening. Despite the active hemorrage, we initiated a third-line treatment with lenalidomide. The response was spectacular.
We report the case of a 71-year-old Caucasian diabetic man with severe diabetic neuropathy who was diagnosed with stage IIIA IgG λ MM in 2004. He was initially treated with three cycles of vincristine, doxorubicin and dexamethasone, followed by high-dose melphalan and autologous stem-cell transplantation, which resulted in a partial response. His monoclonal IgG had dropped from 65 g/L before treatment to 11 g/L after transplantation. In 2007, a second-line chemotherapy treatment (melphalan and prednisone, six cycles) for a relapse characterized by diffuse spinal involvement and an increase in monoclonal IgG (22 g/L) stabilized the disease. His neuropathy had precluded treatment with thalidomide or bortezomib. Eight months after the second-line chemotherapy, an irradiation to the T10-L1 vertebrae (30 Gy) was undertaken for symptomatic, localized bone involvement. Ten months later, an increase in his level of IgG (34 g/L), combined with widespread bone pain and a worsening of his general condition, led to the introduction of high-dose steroids.
Gastrointestinal involvement in MM is very rare. It most often occurs in the context of an isolated, primary, extramedullary plasmacytoma . Patients with newly-diagnosed MM rarely present with symptoms related to gastrointestinal involvement . A gastrointestinal relapse in patients with long-term MM, such as that observed in the case of our patient, is exceptional. Amongst a total of 553 patients with MM included in two large European studies, 87 experienced an extramedullary relapse but none of these involved the gastrointestinal tract [1, 2]. Only one out of six extramedullary relapses reported by a North American Institution involved the gastrointestinal tract . All of these cases had a poor prognosis, with a maximal survival rate of 106 days from diagnosis. Finally, Dawson et al. reported the case of a 60-year-old patient with MM with hematemesis, melena and gastroduodenal mucosal lesions . The patient died two weeks after presentation. The gastrointestinal lesions were not biopsied, but their myelomatous nature was likely, as a biopsy of a right breast mass provided pathological evidence of an extramedullary relapse.
Our case report is well documented and highly informative. It reminds us that, in addition to much more common causes (for example, ulcers), clinicians must consider digestive tract involvement in patients with MM presenting with a gastrointestinal hemorrhage. It also shows that patients with MM who have been heavily pre-treated can benefit from novel drugs, even when they are critically ill. We suggest that the major clinical improvement has to be linked to lenalidomide, since high-dose steroids had been ineffective in this case. Our patient's recovery and the drop in his monoclonal IgG were very rapid. This effect of lenalidomide has already been observed in other life-threatening situations associated with MM, such as severe renal impairment or high-output heart failure secondary to intramedullary arteriovenous fistulas [9, 10]. Finally, it should be emphasized that a response to this oral drug was obtained despite active bleeding in the upper digestive tract.
Written informed consent was obtained from the patient's next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Damaj G, Mohty M, Vey N, Dincan E, Bouabdallah R, Faucher C, Stoppa AM, Gastaut JA: Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol. 2004, 73: 402-406. 10.1111/j.1600-0609.2004.00331.x.View ArticlePubMedGoogle Scholar
- Zeiser R, Deschler B, Bertz H, Engelhardt M: Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant. 2004, 34: 1057-1065. 10.1038/sj.bmt.1704713.View ArticlePubMedGoogle Scholar
- Cerny J, Fadare O, Hutchinson L, Wang SA: Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol. 2008, 81: 65-69. 10.1111/j.1600-0609.2008.01087.x.View ArticlePubMedGoogle Scholar
- Dawson MA, Polizzotto MN, Gordon A, Roberts SK, Spencer A: Extramedullary relapse of multiple myeloma presenting as hematemesis and melena. Nat Clin Pract Oncol. 2006, 3: 223-226. 10.1038/ncponc0454.View ArticlePubMedGoogle Scholar
- Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study Investigators: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007, 357: 2133-2142. 10.1056/NEJMoa070596.View ArticlePubMedGoogle Scholar
- Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010, 11 (1): 29-37. 10.1016/S1470-2045(09)70284-0.View ArticlePubMedGoogle Scholar
- Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B, Arnold W: Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999, 85: 2305-2314. 10.1002/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
- Herbst A, Renner SW, Ringenberg QS, Fass R, Krouse RS: Multiple myeloma presenting with a colonic obstruction and bony lesions: a clinical dilemma. J Clin Oncol. 2008, 26: 5645-5647. 10.1200/JCO.2008.18.6239.View ArticlePubMedGoogle Scholar
- Ludwig H, Zojer N: Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nat Rev Clin Oncol. 2010, 7 (5): 289-294. 10.1038/nrclinonc.2010.31.View ArticlePubMedGoogle Scholar
- Robin J, Fintel B, Pikovskaya O, Davidson C, Cilley J, Flaherty J: Multiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of the literature. J Med Case Reports. 2008, 2: 229-10.1186/1752-1947-2-229.View ArticlePubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.